Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of GRIFFIN

BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial

Updated Results of a Phase 1, First-in-Human Study of ABBV-383, a BCMA × CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Humoral Immune Reconstitution after Quadruplet Therapy, Autologous Hematopoietic Cell Transplant (AHCT) and Measurable Residual Disease adapted Treatment Cessation in Newly Diagnosed Myeloma (NDMM)

Lenalidomide-bortezomib-dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression in patients with newly diagnosed multiple myeloma (NDMM), by cytogenetic risk

Predictors of Unsustained Negativity in Minimal Residual Disease (MRD)-Negative Transplant-Eligible Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the FORTE Trial

Treatment Duration and Long-term Outcomes With Daratumumab in Transplant-ineligible Newly Diagnosed Multiple Myeloma From the Phase 3 MAIA Study

Subcutaneous isatuximab administration by an on-body delivery system in combination with pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: interim phase 1b study results

Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC220-MM-001 trial

A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels

Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)–related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Final Overall Survival Analysis

Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Randomized phase 2 study of weekly Carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in Relapsed and/or refractory Multiple (MM) patients (GEM-KyCyDex)